A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

ClinicalTrials.gov ID: NCT00293930

Public ClinicalTrials.gov record NCT00293930. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis

Study identification

NCT ID: NCT00293930
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 645 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

Tacrolimus Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Nov 2006 (Actual)
Last update posted: Dec 24, 2007

Ends 2006

United States locations

U.S. sites: 26
U.S. states: 21
U.S. cities: 26

Facility	City	State	ZIP	Site status
Not listed	Hot Springs	Arkansas	71913	—
Not listed	San Diego	California	92117	—
Not listed	San Francisco	California	94118	—
Not listed	Longmont	Colorado	80501	—
Not listed	New Haven	Connecticut	06511	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Miami	Florida	33175	—
Not listed	Newnan	Georgia	30263	—
Not listed	Evansville	Indiana	47713	—
Not listed	South Bend	Indiana	46617	—
Not listed	Iowa City	Iowa	52242	—
Not listed	St Louis	Missouri	63117	—
Not listed	New York	New York	10029	—
Not listed	Rochester	New York	14623	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Portland	Oregon	97210	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Bryan	Texas	77802	—
Not listed	Dallas	Texas	75230	—
Not listed	Galveston	Texas	77555	—
Not listed	Burlington	Vermont	05401	—
Not listed	Lynchburg	Virginia	24501	—
Not listed	Dayton	Washington	99328	—
Not listed	Madison	Wisconsin	53719	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00293930, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 24, 2007 · Synced Nov 6, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00293930 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →